Novartis temporarily suspended the production of the company’s Lutathera and Pluvicto cancer therapies at facilities in Italy and New Jersey after potential quality issues were discovered in their manufacturing.
https://www.pharmalive.com/wp-content/uploads/2022/04/ReutersHealthNovartisbuilding.webp7291200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-05-05 13:10:312022-05-06 12:16:52Novartis suspends two cancer therapies over quality concerns